Drug Profile
Research programme: intranasal pneumococcal vaccine - BlueWillow Biologics
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator NanoBio Corporation
- Developer BlueWillow Biologics
- Class Pneumococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Pneumococcal infections
Most Recent Events
- 07 May 2018 NanoBio Corporation is now called BlueWillow Biologics
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pneumococcal-infections in USA (Intranasal)